# Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

> **NCT04200443** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 96 (actual)

## Conditions studied

- Metastatic Leiomyosarcoma
- Metastatic Soft Tissue Sarcoma
- Stage III Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8
- Unresectable Leiomyosarcoma
- Unresectable Soft Tissue Sarcoma

## Interventions

- **DRUG:** Cabozantinib
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04200443
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-14
- **Primary completion:** 2025-04-04
- **Final completion:** 2026-09-10
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2026-05-01

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04200443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04200443, "Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04200443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*